September 5, 2024 06:45 AM EDTUpdated 08:25 AM
R&D

Lil­ly un­veils more pos­i­tive late-stage da­ta for its once-week­ly in­sulin

Katherine Lewin

News Reporter

On Thurs­day, Eli Lil­ly dropped more da­ta for its once-week­ly in­sulin can­di­date in adults with type 2 di­a­betes.

In two Phase 3 tri­als, dubbed QWINT …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times